Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy
2022
Abstract
In this study, we document that MitoTam efficiently kills a range of renal cancer cells and suppresses renal carcinomas in a mouse model by a complex effect on mitochondria, resulting in decreased tumorigenesis. The fact that monotherapy of MitoTam proved to be as efficient in our animal model as immunotherapy is highly encouraging, especially given the fact that renal cancer patients respond poorly to standard chemotherapy.
Our study therefore suggests a novel strategy for treatment of renal cancer by targeting mitochondria in combination with immunotherapy.